
mainboard • BSE, NSE
Nephrocare Health Services
₹32.02
Est. listing gain: 6.96%
Last updated: 2 Jan 2026 12:03 am
Overall Subscription Details: 14.08 times
Open
Dec 10, 2025
Close
Dec 12, 2025
BOA
15 Dec 2025
Refunds
16 Dec 2025
Listing
17 Dec 2025
Pricing & Lot
Price Band
₹438-460
Face Value
₹2 Per Equity Share
Lot Size
TBA
Managers & Listing
Listing At
BSE, NSE
Lead Managers
ICICI Securities Limited/nAmbit Pvt.Ltd IIFL Capital Services Ltd. Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Registrar
Kfin Technologies Limited
Issue Size
1,89,35,819 shares(aggregating up to ₹871.05 crore)
| Investor Category | Shares Offered | Percentage |
|---|---|---|
| Anchor Investor Shares Offered | 5657919 (29.88%) | 29.88% |
| QIB Shares Offered | 3768224 (19.9%) | 19.90% |
| NII (HNI) Shares Offered | 2827843 (14.93%) | 14.93% |
| bNII > ₹10L | 1885229 (10%) | 10.00% |
| sNII < ₹10L | 942614 (5%) | 5.00% |
| Retail Shares Offered | 6598301 (34.85%) | 34.85% |
| Employee Shares Offered | 83532 (0.44%) | 0.44% |
| Total Shares Offered | 18935819 (100%) | 100.00% |
GMP (per share)
₹32.02
Est. Listing Price
₹492.02
Total Listing Gain (per lot)
₹0.00
Grey Market Premium (GMP) is an unofficial market indicator. It reflects the premium investors are willing to pay over the issue price before listing. This is not a guaranteed return and can change rapidly.
Nephrocare Health Services Ltd, incorporated in the year 2010, is an end-to-end dialysis care provider through its wide network of clinics across India and select international markets. It offers services such as diagnosis, haemodialysis, home and mobile dialysis, and wellness programs, supported by an in-house pharmacy. As of March 31, 2025, Nephrocare operated 490 clinics—447 in India and 43 across the Philippines, Uzbekistan, and Nepal. This includes the world’s largest dialysis clinic in Uzbekistan. In India, the company had a presence across 269 cities in 21 States and four Union Territories. Approximately 76.73% of its clinics were located in tier II and tier III cities, addressing a critical need in underserved regions. In Fiscal 2025, Nephrocare treated 29,281 patients and performed more than 2.88 million dialysis treatments, amounting to approximately 10% of the country's total dialysis patient base. The number of dialysis machines operated by the company increased to 5,068 as of March 2025 from 4,714 in Fiscal 2024 and 3,662 in Fiscal 2023. Nephrocare has formulated strategic alliances with leading hospital chains like Max Super Speciality Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital, and Ruby Hall Clinic to operate in-house dialysis centers. As of March 2025, the workforce consisted of 3,230 employees, including both medical and administrative staff working across its clinics and corporate office.
Name
Kfin Technologies Limited
GainIPO data last updated: 01 Jan 2026, 06:33 PM IST